Title: Faculty & research interests





Robin S Goland
Robin S Goland, MD
Prof of Clinical Medicine and Pediatrics
Co-Director, Naomi Berrie Diabetes Ctr

Associate Member

Department: Medicine

Russ Berrie 2
212 851 5492

Personal Website

Disease Models: Endocrinological Diseases

Stem Cell Categories: ES and other embryonic stem cells, iPS cells

Model Organisms: Human

Themes: Internal Organs

Dr. Goland, along with co-director Dr. Rudolph Leibel, leads the Naomi Berrie Diabetes Center at Columbia University Medical Center in New York City, combining premier family-centered patient care and education with world-class diabetes research programs. The Berrie Center's patient population, now numbering more than 10,000 people, is extraordinarily diverse, including patients of diverse ages, ethnic backgrounds, and socioeconomic status. The clinical space is directly adjacent to research laboratories working on prevention, treatment and ultimately cure of diabetes. Because of close collaboration between clinicians and investigators at the Berrie Center, advances made at the research bench are made available to the patients as rapidly as possible. A major focus of the Dr. Goland's work is on translational research adult and pediatric patients with type 1 diabetes and type 2 diabetes, including studies on diabetes-specific embryonic stem cells.


Maehr, R., Chen, S., Snitow, M., Ludwig, T., yagasaki, L., Goland, R.,Leibel, R.L., Meltom, D.A. (2009)
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci 106(37):15768-73. (2009)

Dimos, J., Rodolfa, K., Niakan, K., Weisenthal, L.,Mitsumoto, H., Chung, W., Croft, G., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C.,and Eggan, K.(2008)
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893):1218-21. (2008)

Today Study Group (2007)
Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 8(2):74-87. (2007)

Pescovitz, M., Greenbaum, C., Becker, D., Krause-Steinraus H., Gitelman, S., Goland, R.,Marks, J., McGee, P., Moran, A., Raskin, P., Rodriguez, H., Schatz, D., Wherrett, D., Wilson, D., Lachin, J., Skyler, J., and the Type 1 Diabetes AntiCD20 Stud
Preservation of beta-cell function by B-lymphocyte depletion with rituximab in patients with new onset autoimmune diabetes. New Eng J Med 361:22:2143-2152. ()

Goland, R., Freeby, M., Ichise, M., Parsey, R., Kessler, D., Saisho, Kumar.K., Murty, R., Mikno, A., Desimone, K., Simpson, N., Saxcena, C., Cung, M., Farwell, M., Plett, S., Dashnaw, S., Hirsch, J., Prince,M., Maffei, A., Mann, J., Butler, P., Va
Beta cell mass measurements by PET scan using [11C] dihydrotetrabenazine in subjects with type 1 diabetes. J Nucl Med 50:382-389. ()

bottom rounded